ey0018.7-5 | Clinical Guidance | ESPEYB18
EV Brauner , AS Busch , C Eckert-Lind , T Koch , M Hickey , A Juul
ey0018.9-1 | Cancer treatment and the risk of second neoplasia | ESPEYB18
NMY Journy , WS Zrafi , S Bolle , B Fresneau , C Alapetite , RS Allodji , D Berchery , N Haddy , I Kobayashi , M Labbe , H Pacquement , C Pluchart , B Schwartz , V Souchard , C Thomas-Teinturier , C Veres , G Vu-Bezin , I Diallo , F de Vathaire
ey0018.9-12 | Cancer treatment, growth and growth hormone therapy | ESPEYB18
SR Rose , M Carlsson , A Grimberg , F Aydin , A Albanese , ACS Hokken-Koelega , C Camacho-Hubner
ey0018.10-11 | (1) | ESPEYB18
H Thabit , JN Prabhu , W Mubita , C Fullwood , S Azmi , A Urwin , I Doughty , L Leelarathna
ey0018.12-7 | Type 2 Diabetes | ESPEYB18
RA Delicano , U Hammar , A Egenvall , C Westgarth , M Mubanga , L Byberg , T Fall , B Kennedy
ey0019.2-1 | Neonatal hypoglycaemia | ESPEYB19
K Gupta , P Amboiram , U Balakrishnan , A C , T Abiramalatha , U Devi
ey0019.4-4 | Important for clinical practice | ESPEYB19
HH Shukur , L Hussain-Alkhateeb , Farholt S , O Norregaard , AP Jorgensen , C Hoybye
ey0019.5-6 | Advances in clinical practice | ESPEYB19
C Zheng , H Li , S Rong , L Liu , K Zhen , K Li
ey0019.6-14 | Gender Incongruence: Wider impacts of gender affirming hormone (GAH) treatments | ESPEYB19
GA Robinson , J Peng , H Peckham , A Radziszewska , G Butler , I Pineda-Torra , EC Jury , C Ciurtin
ey0019.9-15 | Bone health in chronic disease | ESPEYB19
S Rozes , S Guilmin-Crepon , M Alison , E Thomas , JP Hugot , J Viala , C Martinez-Vinson